{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:21:19Z","timestamp":1783693279611,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T00:00:00Z","timestamp":1440028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12886-015-0101-4","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T09:45:18Z","timestamp":1439977518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of Eylea\u00ae with Lucentis\u00ae as first-line therapy in patients with treatment-na\u00efve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Sophie C.","family":"B\u00f6hni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas M.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Faes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,20]]},"reference":[{"issue":"1","key":"101_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57\u201365. e55.","journal-title":"Ophthalmology"},{"issue":"14","key":"101_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"101_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"key":"101_CR4","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2013."},{"issue":"1","key":"101_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","volume":"18","author":"N Ferrara","year":"1997","unstructured":"Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4\u201325.","journal-title":"Endocr Rev"},{"issue":"4","key":"101_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.preteyeres.2008.05.002","volume":"27","author":"S Grisanti","year":"2008","unstructured":"Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008;27(4):372\u201390.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"101_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171\u201385.","journal-title":"Angiogenesis"},{"issue":"4","key":"101_CR8","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1167\/iovs.02-0809","volume":"44","author":"JM Rakic","year":"2003","unstructured":"Rakic JM, Lambert V, Munaut C, Bajou K, Peyrollier K, Alvarez-Gonzalez ML, et al. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(4):1732\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"101_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","volume":"92","author":"MW Stewart","year":"2008","unstructured":"Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol. 2008;92(5):667\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"101_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","volume":"118","author":"U Schmidt-Erfurth","year":"2011","unstructured":"Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831\u20139.","journal-title":"Ophthalmology"},{"issue":"4","key":"101_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566\u201383.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"101_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43\u201358. e41.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"101_CR13","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s12325-013-0078-4","volume":"30","author":"SS Johnston","year":"2013","unstructured":"Johnston SS, Wilson K, Huang A, Smith D, Varker H, Turpcu A. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. Adv Ther. 2013;30(12):1111\u201327.","journal-title":"Adv Ther"},{"key":"101_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/RMHP.S80536","volume":"8","author":"O Reich","year":"2015","unstructured":"Reich O, Bachmann LM, Faes L, Bohni SC, Bittner M, Howell JP, et al. Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data. Risk Manag Healthc Policy. 2015;8:55\u201362.","journal-title":"Risk Manag Healthc Policy"},{"key":"101_CR15","unstructured":"Swiss therapeutic registry: http:\/\/compendium.ch\/prod\/pnr\/1105084\/de and http:\/\/compendium.ch\/prod\/pnr\/1219891\/de 13.03.2014"},{"issue":"1","key":"101_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ajo.2013.03.030","volume":"156","author":"Y Yonekawa","year":"2013","unstructured":"Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29\u201335. e22.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"101_CR17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","volume":"33","author":"N Kumar","year":"2013","unstructured":"Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605\u201312.","journal-title":"Retina"},{"issue":"1","key":"101_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ajo.2013.02.009","volume":"156","author":"VY Ho","year":"2013","unstructured":"Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156(1):23\u20138. e22.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"101_CR19","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00417-014-2589-3","volume":"252","author":"H Fassnacht-Riederle","year":"2014","unstructured":"Fassnacht-Riederle H, Becker M, Graf N, Michels S. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol. 2014;252(11):1705\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"101_CR20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/eye.2014.101","volume":"28","author":"DS Grewal","year":"2014","unstructured":"Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye. 2014;28(7):895\u20139.","journal-title":"Eye"},{"issue":"6","key":"101_CR21","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00417-013-2553-7","volume":"252","author":"FM Heussen","year":"2014","unstructured":"Heussen FM, Shao Q, Ouyang Y, Joussen AM, Muller B. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):909\u201315.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"101_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2013.02.017","volume":"156","author":"B Bakall","year":"2013","unstructured":"Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15\u201322. e11.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"101_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/bjophthalmol-2013-304829","volume":"98","author":"WB Messenger","year":"2014","unstructured":"Messenger WB, Campbell JP, Faridi A, Shippey L, Bailey ST, Lauer AK, et al. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2014;98(9):1205\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"101_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","volume":"29","author":"F Forooghian","year":"2009","unstructured":"Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29(6):723\u201331.","journal-title":"Retina"},{"issue":"12","key":"101_CR25","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"115","author":"S Schaal","year":"2008","unstructured":"Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008;115(12):2199\u2013205.","journal-title":"Ophthalmology"},{"issue":"1","key":"101_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"96","author":"MS Eghoj","year":"2012","unstructured":"Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21\u20133.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"101_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/eye.2013.31","volume":"27","author":"KH Patel","year":"2013","unstructured":"Patel KH, Chow CC, Rathod R, Mieler WF, Lim JI, Ulanski 2nd LJ, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye. 2013;27(5):663\u20137. quiz 668.","journal-title":"Eye"},{"key":"101_CR28","first-page":"343","volume":"8","author":"M Yamashita","year":"2014","unstructured":"Yamashita M, Nishi T, Hasegawa T, Ogata N. Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab. Clin Ophthalmol. 2014;8:343\u20136.","journal-title":"Clin Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-015-0101-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T06:55:33Z","timestamp":1475823333000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-015-0101-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,20]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["101"],"URL":"https:\/\/doi.org\/10.1186\/s12886-015-0101-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,20]]},"article-number":"109"}}